155 related articles for article (PubMed ID: 8445430)
1. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia.
Ito Y; Wasserman R; Galili N; Reichard BA; Shane S; Lange B; Rovera G
J Clin Oncol; 1993 Mar; 11(3):546-53. PubMed ID: 8445430
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
3. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia.
Wasserman R; Galili N; Ito Y; Silber JH; Reichard BA; Shane S; Womer RB; Lange B; Rovera G
J Clin Oncol; 1992 Dec; 10(12):1879-88. PubMed ID: 1453203
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment.
Yamada M; Wasserman R; Lange B; Reichard BA; Womer RB; Rovera G
N Engl J Med; 1990 Aug; 323(7):448-55. PubMed ID: 2095753
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia.
Scholten C; Födinger M; Mitterbauer M; Laczika K; Mitterbauer G; Haas OA; Knöbl P; Schwarzinger I; Thalhammer R; Purtscher B
Ann Hematol; 1995 Oct; 71(4):155-60. PubMed ID: 7578520
[TBL] [Abstract][Full Text] [Related]
6. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
Potter MN; Steward CG; Oakhill A
Br J Haematol; 1993 Mar; 83(3):412-8. PubMed ID: 8485046
[TBL] [Abstract][Full Text] [Related]
7. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
[TBL] [Abstract][Full Text] [Related]
8. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
9. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.
Estrov Z; Ouspenskaia MV; Felix EA; McClain KL; Lee MS; Harris D; Pinkel DP; Zipf TF
Leukemia; 1994 Jan; 8(1):46-52. PubMed ID: 8289497
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
11. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia.
Kitchingman GR
Leukemia; 1994 Mar; 8(3):395-401. PubMed ID: 8127144
[TBL] [Abstract][Full Text] [Related]
12. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
[TBL] [Abstract][Full Text] [Related]
14. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group.
Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I
Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.
Biondi A; Yokota S; Hansen-Hagge TE; Rossi V; Giudici G; Maglia O; Basso G; Tell C; Masera G; Bartram CR
Leukemia; 1992 Apr; 6(4):282-8. PubMed ID: 1316978
[TBL] [Abstract][Full Text] [Related]
18. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
[TBL] [Abstract][Full Text] [Related]
19. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
Paganin M; Fabbri G; Conter V; Barisone E; Polato K; Cazzaniga G; Giraldi E; Fagioli F; Aricò M; Valsecchi MG; Basso G
J Clin Oncol; 2014 Nov; 32(31):3553-8. PubMed ID: 25287825
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
Brisco MJ; Condon J; Hughes E; Neoh SH; Sykes PJ; Seshadri R; Toogood I; Waters K; Tauro G; Ekert H
Lancet; 1994 Jan; 343(8891):196-200. PubMed ID: 7904666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
